Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17106596rdf:typepubmed:Citationlld:pubmed
pubmed-article:17106596lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:17106596lifeskim:mentionsumls-concept:C0011053lld:lifeskim
pubmed-article:17106596lifeskim:mentionsumls-concept:C1710263lld:lifeskim
pubmed-article:17106596lifeskim:mentionsumls-concept:C0026882lld:lifeskim
pubmed-article:17106596lifeskim:mentionsumls-concept:C0050559lld:lifeskim
pubmed-article:17106596lifeskim:mentionsumls-concept:C0265336lld:lifeskim
pubmed-article:17106596lifeskim:mentionsumls-concept:C0205182lld:lifeskim
pubmed-article:17106596lifeskim:mentionsumls-concept:C0265964lld:lifeskim
pubmed-article:17106596lifeskim:mentionsumls-concept:C1415077lld:lifeskim
pubmed-article:17106596lifeskim:mentionsumls-concept:C0163742lld:lifeskim
pubmed-article:17106596lifeskim:mentionsumls-concept:C0332293lld:lifeskim
pubmed-article:17106596pubmed:issue6lld:pubmed
pubmed-article:17106596pubmed:dateCreated2006-11-19lld:pubmed
pubmed-article:17106596pubmed:abstractTextNeuroectodermal syndromes involving the skin and inner ear may be associated with mutations in connexin proteins, which form gap junctions important for intercellular communication. Vohwinkel syndrome (keratodermia mutilans with hearing loss) and keratitis-ichthyosis-deafness (KID) syndrome are rare ectodermal dysplasias associated with dominant mutations in the GJB2 gene encoding connexin 26. We report here two patients, one with KID and one with Vohwinkel syndrome. Both displayed unusual clinical features and responded well to long-term treatment with oral retinoid. Mutation analysis revealed a novel GJB2 mutation p.Gly59Ser in the patient with Vohwinkel syndrome, whereas a recurrent mutation p.Asp50Asn was found in the patient with KID syndrome. The clinical features, particularly a proneness to skin cancer in the patient with Vohwinkel syndrome, are discussed in relation to the identified genotypes.lld:pubmed
pubmed-article:17106596pubmed:languageenglld:pubmed
pubmed-article:17106596pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17106596pubmed:citationSubsetIMlld:pubmed
pubmed-article:17106596pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17106596pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17106596pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17106596pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17106596pubmed:statusMEDLINElld:pubmed
pubmed-article:17106596pubmed:issn0001-5555lld:pubmed
pubmed-article:17106596pubmed:authorpubmed-author:BondesonMarie...lld:pubmed
pubmed-article:17106596pubmed:authorpubmed-author:VahlquistAnde...lld:pubmed
pubmed-article:17106596pubmed:authorpubmed-author:NyströmAnna-M...lld:pubmed
pubmed-article:17106596pubmed:authorpubmed-author:GunnarssonUlr...lld:pubmed
pubmed-article:17106596pubmed:issnTypePrintlld:pubmed
pubmed-article:17106596pubmed:volume86lld:pubmed
pubmed-article:17106596pubmed:ownerNLMlld:pubmed
pubmed-article:17106596pubmed:authorsCompleteYlld:pubmed
pubmed-article:17106596pubmed:pagination503-8lld:pubmed
pubmed-article:17106596pubmed:meshHeadingpubmed-meshheading:17106596...lld:pubmed
pubmed-article:17106596pubmed:meshHeadingpubmed-meshheading:17106596...lld:pubmed
pubmed-article:17106596pubmed:meshHeadingpubmed-meshheading:17106596...lld:pubmed
pubmed-article:17106596pubmed:meshHeadingpubmed-meshheading:17106596...lld:pubmed
pubmed-article:17106596pubmed:meshHeadingpubmed-meshheading:17106596...lld:pubmed
pubmed-article:17106596pubmed:meshHeadingpubmed-meshheading:17106596...lld:pubmed
pubmed-article:17106596pubmed:meshHeadingpubmed-meshheading:17106596...lld:pubmed
pubmed-article:17106596pubmed:meshHeadingpubmed-meshheading:17106596...lld:pubmed
pubmed-article:17106596pubmed:meshHeadingpubmed-meshheading:17106596...lld:pubmed
pubmed-article:17106596pubmed:meshHeadingpubmed-meshheading:17106596...lld:pubmed
pubmed-article:17106596pubmed:meshHeadingpubmed-meshheading:17106596...lld:pubmed
pubmed-article:17106596pubmed:meshHeadingpubmed-meshheading:17106596...lld:pubmed
pubmed-article:17106596pubmed:meshHeadingpubmed-meshheading:17106596...lld:pubmed
pubmed-article:17106596pubmed:meshHeadingpubmed-meshheading:17106596...lld:pubmed
pubmed-article:17106596pubmed:meshHeadingpubmed-meshheading:17106596...lld:pubmed
pubmed-article:17106596pubmed:year2006lld:pubmed
pubmed-article:17106596pubmed:articleTitleConnexin 26 (GJB2) mutations in two Swedish patients with atypical Vohwinkel (mutilating keratoderma plus deafness) and KID syndrome both extensively treated with acitretin.lld:pubmed
pubmed-article:17106596pubmed:affiliationDepartment of Genetics and Pathology, University of Uppsala, Sweden. marielouise.bondeson@genpat.uu.selld:pubmed
pubmed-article:17106596pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:17106596pubmed:publicationTypeCase Reportslld:pubmed
pubmed-article:17106596pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed